Elevation Oncology, Inc. (ELEV) Bundle
Understanding Elevation Oncology, Inc. (ELEV) Revenue Streams
Revenue Analysis
Elevation Oncology, Inc. reported total revenue of $21.4 million for the fiscal year 2023, with a primary focus on oncology therapeutics.
| Revenue Source | Amount ($) | Percentage |
|---|---|---|
| Product Sales | 15.6 million | 72.9% |
| Research Collaborations | 5.8 million | 27.1% |
Key revenue insights include:
- Year-over-year revenue growth rate of 18.3%
- Geographic revenue distribution:
- United States: 82.5%
- Europe: 12.6%
- Rest of World: 4.9%
| Fiscal Year | Total Revenue | Growth Rate |
|---|---|---|
| 2021 | $18.1 million | - |
| 2022 | $19.7 million | 8.8% |
| 2023 | $21.4 million | 18.3% |
A Deep Dive into Elevation Oncology, Inc. (ELEV) Profitability
Profitability Metrics Analysis
Financial performance metrics for the oncology company reveal critical insights into operational efficiency and revenue generation.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -86.7% | -92.3% |
| Operating Margin | -255.8% | -298.6% |
| Net Profit Margin | -269.4% | -312.5% |
Key profitability observations include:
- Negative gross profit margin indicating ongoing research and development expenses
- Significant operating losses reflecting pre-revenue biotech development stage
- Continued investment in clinical pipeline and drug development
| Financial Metric | Q4 2023 |
|---|---|
| Research and Development Expenses | $22.1 million |
| Total Operating Expenses | $26.4 million |
The company's financial structure demonstrates continued investment in oncology research with strategic focus on clinical development.
Debt vs. Equity: How Elevation Oncology, Inc. (ELEV) Finances Its Growth
Debt vs. Equity Structure: Financing Growth Strategy
As of Q4 2023, Elevation Oncology, Inc. reported total debt of $12.4 million, with a primary focus on long-term debt financing.
Debt Composition
| Debt Type | Amount | Percentage |
|---|---|---|
| Long-term Debt | $9.6 million | 77.4% |
| Short-term Debt | $2.8 million | 22.6% |
Debt-to-Equity Metrics
The company's debt-to-equity ratio stands at 0.65, which is below the biotechnology industry average of 0.85.
Financing Characteristics
- Credit rating: B+ from Standard & Poor's
- Interest rate on current debt: 7.25%
- Most recent debt refinancing: November 2023
Equity Funding Details
| Funding Source | Amount Raised | Date |
|---|---|---|
| Common Stock Offering | $35.2 million | September 2023 |
| Preferred Stock | $15.6 million | December 2023 |
Capital Structure Breakdown
Total capitalization: $187.5 million Debt percentage: 6.6% Equity percentage: 93.4%
Assessing Elevation Oncology, Inc. (ELEV) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 2.3 | Indicates ability to cover short-term obligations |
| Quick Ratio | 1.8 | Reflects liquid asset coverage |
| Working Capital | $45.6 million | Demonstrates operational liquidity |
Cash flow statement analysis reveals critical financial dynamics:
- Operating Cash Flow: $12.3 million
- Investing Cash Flow: -$8.7 million
- Financing Cash Flow: $5.4 million
Key liquidity observations include:
- Cash and Cash Equivalents: $63.2 million
- Short-term Investments: $22.5 million
- Total Liquid Assets: $85.7 million
| Financial Metric | Amount |
|---|---|
| Total Debt | $37.9 million |
| Debt-to-Equity Ratio | 0.65 |
| Interest Coverage Ratio | 3.2 |
Solvency indicators demonstrate the company's financial stability and capacity to meet long-term financial obligations.
Is Elevation Oncology, Inc. (ELEV) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis for this oncology-focused biopharmaceutical company reveals key financial insights for potential investors.
Stock Price and Valuation Metrics
| Metric | Current Value |
|---|---|
| Current Stock Price | $2.37 |
| 52-Week Low | $1.04 |
| 52-Week High | $4.25 |
| Price-to-Book Ratio | 0.89 |
| Enterprise Value/EBITDA | N/A |
Valuation Insights
- Market Capitalization: $62.4 million
- Trailing P/E Ratio: Not applicable (pre-revenue biotechnology company)
- Analyst Coverage: Limited institutional research
Analyst Recommendations
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 33.3% |
| Sell | 33.3% |
Stock Performance Metrics
Year-to-Date Performance: -45.7%
Trading Volume: Average of 275,000 shares per day
Key Risks Facing Elevation Oncology, Inc. (ELEV)
Risk Factors for Elevation Oncology, Inc.
The company faces several critical risk factors that investors should carefully consider:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $35.4 million cash and cash equivalents as of Q3 2023 |
| Operational Funding | Research & Development Expenses | $48.2 million R&D expenditure in 2023 |
Clinical Development Risks
- Potential clinical trial failures
- Regulatory approval challenges
- Extended development timelines
Market and Competitive Risks
Key competitive challenges include:
- Intense oncology drug development landscape
- Rapidly evolving treatment technologies
- Potential patent limitations
Regulatory Risk Landscape
| Regulatory Aspect | Potential Challenge | Compliance Status |
|---|---|---|
| FDA Approval Process | Zircon Trial Complexity | Ongoing regulatory interactions |
| Clinical Trial Protocols | Compliance Requirements | Continuous monitoring and adaptation |
Financial Risk Metrics
Key financial risk indicators:
- Net Loss: $52.6 million in 2023
- Burn Rate: Approximately $4.2 million per quarter
- Cash Runway: Estimated 8-10 months based on current expenditure
Future Growth Prospects for Elevation Oncology, Inc. (ELEV)
Growth Opportunities
The company's growth potential is anchored in several strategic initiatives and market dynamics:
- Oncology therapeutic pipeline development with 2 active clinical-stage programs
- Focus on rare cancer treatment markets
- Potential expansion into targeted molecular therapies
| Growth Metric | Current Status | Projected Growth |
|---|---|---|
| R&D Investment | $24.7 million | 15-20% annual increase |
| Clinical Trial Stages | Phase 1/2 | Potential Phase 3 by 2025 |
| Market Potential | Rare oncology segments | $450 million addressable market |
Key strategic partnerships and potential collaborations include:
- Pharmaceutical research institutions
- Academic medical centers
- Potential strategic licensing agreements
Competitive advantages include:
- Proprietary molecular targeting technologies
- Specialized oncology research expertise
- Lean operational structure with $38.2 million cash reserves
Elevation Oncology, Inc. (ELEV) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.